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ABSTRACT 
Purpose: This study aimed to document the matching of muscle O2 delivery-to-O2 utilisation 
in young patients with cystic fibrosis (CF) patients from muscle deoxygenation (HHb) 
dynamics during ramp exercise. Methods: Ten patients with stable, mild-to-moderate CF 
(12.7 ± 2.8 y) and 10 healthy controls (CON; 12.8 ± 2.8 y) completed a combined ramp and 
supramaximal cycling test to determine maximal O2 uptake (V̇O2max). Changes in gas 
exchange and ventilation, heart rate and m. vastus lateralis HHb (near-infrared spectroscopy) 
were assessed. Δ[HHb]-work rate and Δ[HHb]-V̇O2 profiles were normalised and fit using a 
sigmoid function. Results: Aerobic function was impaired in CF, indicated by very likely 
reduced fat-free mass normalized V̇O2max (mean difference, ±90% CI: -7.9 mL·kg
-1
·min
-1
, 
±6.1), very likely lower V̇O2 gain (-1.44 mL·min
-1
·W
-1
, ±1.12) and a likely slower V̇O2 mean 
response time (11 s, ±13). An unclear effect was found upon the absolute and relative WR (-
14 W, ±44 and -0.7 %PPO, ±12.0, respectively) and the absolute and percentage (-0.10 
L·min
-1
, ±0.43 and 3.3 %V̇O2max, ±6.0) V̇O2 corresponding to 50% Δ[HHb] amplitude, 
respectively, between groups. However, arterial oxygen saturation (SpO2) was very likely 
lower in CF (-1%, ±1) and demonstrated moderate-to-very large relations with parameters of 
aerobic function. Conclusion: Young patients with mild-to-moderate CF present with 
impaired aerobic function during ramp incremental cycling exercise. Because the rate of 
fractional O2 extraction during ramp cycling exercise was not altered by CF, yet SpO2 was 
lower, the present findings support the notion of centrally mediated oxygen delivery to 
principally limit the aerobic function of pediatric patients with CF during ramp incremental 
cycling exercise.  
 
Keywords: Near-infrared spectroscopy, aerobic function, exercise testing, exercise 
limitation, lung disease, paediatrics. 
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INTRODUCTION 
Paragraph 1: Cystic fibrosis (CF) is a complex multiorgan genetic disease, expressed as a 
disruption in the CF transmembrane conductance regulator (CFTR) protein. In conjunction 
with its clinical presentation, reduced aerobic fitness (typically determined as maximal 
oxygen uptake (V̇O2max)), is commonly observed in both adult (10) and paediatric patients 
(17). Reduced aerobic fitness is of clinical relevance in patients with CF, given its association 
with longevity (25,28), quality of life (6) and risk of hospitalisation (26). Key parameters of 
aerobic function (i.e., V̇O2max, V̇O2 gain, gas exchange threshold (GET), and V̇O2 mean 
response time (MRT)) (37) have not, however, been comprehensively documented in CF. 
Moreover, no previous studies have used a valid protocol (30) to obtain a ‘true’ measure of 
V̇O2max in this population. Identifying the limiting factor(s) impairing aerobic function in CF 
will facilitate the development of more effective strategies to improve longevity and quality 
of life in this aging patient population. 
Paragraph 2: Because the body’s upper limit for V̇O2 use is determined by the 
maximal cardiac output (?̇?), arterial V̇O2 content, fractional distribution of ?̇? to the exercising 
muscles, and the ability of the skeletal muscle to extract O2 (35), simultaneous measurements 
at the central (cardiorespiratory) and peripheral (skeletal muscle) levels are required to 
understand the dynamic matching of O2 delivery-to-O2 utilisation during exercise. Previous 
studies in CF have, however, largely neglected this complex interaction and based inferences 
on investigations of isolated organ systems (e.g.8,16,20).  
Paragraph 3: As a result, debate remains regarding the relative importance of central 
and peripheral mechanisms to explain the reduced V̇O2max in patients with mild-to-moderate 
CF. Expression of CFTR in the human skeletal muscle (19) suggests an intrinsic myocyte 
metabolic abnormality, which may be specific to CF (e.g.7,8) or a consequence of chronic 
respiratory disease (30,36).  In addition, there is evidence to support a central limitation to 
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exercise through a reduction in stroke volume (SV) (27) and, presumably, muscle O2 delivery 
(29), in pediatric patients with CF. Although a compensatory increase in muscle O2 extraction 
may be expected to occur in the presence of reduced muscle O2 delivery, this was not 
observed in a previous study (29). However, further confirmation of this response is 
warranted because inferences at the skeletal muscle level were based upon indirect, 
interlinked mathematical calculations.  
  Paragraph 4: To further understand how disease pathophysiology alters the O2 
delivery-to-O2 utilisation relationship during exercise, near-infrared spectroscopy (NIRS) can 
provide valuable, non-invasive insight into peripheral O2 extraction. Specifically, the profile 
of the deoxyhemoglobin ([HHb]) signal has been used to describe O2 extraction dynamics 
during ramp exercise, which in turn permit inferences regarding blood flow within the 
microcirculation of exercising muscle (4,9,23,24,25). Although the[HHb] profile during ramp 
exercise has been used to describe the effect of trained status (4,21) and ageing (11,21), there 
are no data documenting the influence of disease on the [HHb] response to incremental 
exercise. If the supply of blood to the active muscle during exercise is impaired in CF, as 
would be indirectly inferred from previous reports of a reduced SV (27), an increased rate of 
fractional O2 extraction for a given V̇O2 would be expected (9).  
Paragraph 6: The purpose of the present study was twofold; 1) to characterise the 
four key parameters of aerobic function in pediatric patients with mild-to-moderate CF and 2) 
to characterize the dynamic adjustment of NIRS-derived leg muscle [HHb] during ramp 
exercise. It was hypothesised that: 1) aerobic function would be impaired in CF, as evidenced 
by a reduced V̇O2max, slower V̇O2 MRT, earlier occurrence of the GET and shallower V̇O2 
gain and, furthermore, that 2) patients with CF would be characterized by more rapid [HHb] 
dynamics during ramp exercise (i.e., leftward shift), which will correlate with impaired 
parameters of aerobic function.   
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MATERIALS and METHODS  
Paragraph 7: Study participants. Ten young patients (9 males (Table 1)) with stable mild-
to-moderate CF disease (CF) regularly partaking in school and/or extracurricular physical 
activity were recruited from outpatient clinics at the Royal Devon and Exeter NHS 
Foundation Trust Hospital. CF inclusion and exclusion criteria are detailed elsewhere (30). 
Ten healthy age- and gender- matched control participants (CON) were recruited from the 
local area (Table 1). Neither group presented with any contraindications to exhaustive 
exercise, and CON were free from any pulmonary conditions. Ethics approval was granted by 
the South West NHS Research Ethics Committee. Informed written consent and assent were 
obtained from parents/guardians and patients, respectively. Details concerning the CF 
patients’ disease severity and clinical profile were obtained by their clinician (Table 2). All 
CF maintenance medications were continued as usual throughout the study. 
 
 
Paragraph 8: Anthropometry and pulmonary function. Body mass (Seca 220; Vogel & 
Halke, Hamburg, Germany) and stature (Seca 220; Vogel & Halke, Hamburg, Germany) 
were measured to the nearest 0.01 kg and 0.01 m, respectively. Pubertal maturity was 
determined using Tanner staging (34). Skin folds measured to the nearest 1 mm on the right-
hand side of the body at the tricep and subscapula regions (Harpenden; British Indicators, 
Burgess Hill, UK) were used to estimate fat-free mass (FFM) (32). Forced vital capacity 
(FVC) and forced expiratory volume in 1 s (FEV1) were assessed using flow-volume loop 
spirometry (MicroMedical MicroLoop 3535, Numed, Sheffield, UK). The best of three 
consistent (< 5% variability) exhalations was documented and expressed as a percentage of 
predicted reference data (33).  
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Paragraph 9: Exercise testing. Participants arrived to the laboratory in a rested state, ≥ 2 h 
postprandial and having refrained from caffeine for ≥ 2 h. A maximal cardiopulmonary 
exercise test (CPET) was performed on a cycle ergometer (Lode Excalibur or Lode Corival, 
Groningen, The Netherlands) using a single session, combined ramp incremental and 
supramaximal CPET protocol, which has been validated in healthy children (1) and children 
with CF (30). This protocol, the reproducibility of which has recently been documented in 
young CF patients (32), involved an exhaustive ramp incremental (10-25 W∙min-1) cycling 
test with a subsequent supramaximal (110% peak power output (PPO)) test to exhaustion to 
verify V̇O2max. After a 3-min warm-up period (20 W cycling), participants completed the 
incremental ramp test while cycling at a cadence of approximately 70-80 rpm until volitional 
exhaustion, defined as a drop in cadence ≥ 10 rpm for five consecutive seconds, despite 
strong verbal encouragement. Five-minute active recovery (20 W cycling) and 10-min 
passive seated recovery then preceded the Smax verification test, which involved a 3-min 
warm-up (20 W cycling) before a “step” transition to a constant work rate (WR) equivalent to 
110% PPO. Upon voluntary exhaustion, 5-min active recovery (20 W cycling) completed the 
CPET assessment.  
 
Experimental measures 
Paragraph 10:  Before each test, the metabolic cart (Metalyzer 3B Cortex, Biophysik, 
Leipzig, Germany) was calibrated using gases of known concentration and a 3-L calibration 
syringe (Hans Rudolph, Kansas City, MO) was used to calibrate the turbine volume 
transducer. Breath-by-breath changes in pulmonary gas exchange and ventilation were 
measured and averaged to 15-s time bins, with the highest 15-s stationary average from the 
ramp or Smax representing V̇O2max (11). The GET in absolute terms and expressed as a 
percentage of V̇O2max was non-invasively identified (1) and confirmed through visual 
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identification of the ventilatory equivalents for V̇O2 and carbon dioxide output (V̇CO2). The 
V̇O2 mean response time (MRT) was determined using the time from the onset of ramp 
exercise to the intersection point between baseline V̇O2 and a backward extrapolation of the 
slope of V̇O2 as a function of time (37). Regression of the linear portion of the V̇O2 response 
versus power output was used to determine the functional V̇O2 gain (∆V̇O2/∆WR). Equation 1 
was used to determine oxygen pulse (V̇O2/peak heart rate (HRpeak)).  
 
V̇O2/HRpeak (mL∙beat
-1
) = V̇O2 (L∙min
-1
) x 1000 mL / HR (beats∙min-1)               Equation 1. 
 
Paragraph 11: Near-infrared spectroscopy. HHb dynamics from the m. vastus lateralis 
were noninvasively measured using NIRS (Portamon, Artinis Medical Systems). This system 
has previously been used in children (21) and consists of an emission probe, with three light 
sources emitting two wavelengths of light (760 and 850 nm) and a photon detector. The 
intensity of incident and transmitted light was recorded continuously at 10 Hz and used to 
estimate [HHb]. Since the NIRS-derived [HHb] signal does encompass contribution from 
intramyocyte myoglobin and does not solely reflect the microcirculatory compartment 
[vascular (Hb) deoxygenation] (18), the changes in muscle HHb should be considered to 
represent [Hb+Mb]. The wireless emitter-detector unit was placed over the m. vastus 
lateralis, midway between the greater trochanter and lateral epicondyle of the femur. The 
area of interrogation was initially cleaned and shaved and, after marking of the placement 
area, the device was secured with tape (KinesioTex
®
) and a dark elastic bandage, to minimize 
extraneous light interference with the near-infrared signal.  
 
Paragraph 12: Additional measures: HR was measured on a beat-by-beat basis using the 
ECG-derived R-R interval (PhysioFlow, PF-05, Manatec Biomedical, Paris, France). 
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Fingertip arterial oxygen saturation (SpO2%) was recorded via pulse oximetry (NONIN, 
Avant 4000, NONIN Medical Inc., USA). Subjective ratings of perceived exertion (RPE) and 
dyspnoea (RPD) were determined upon exhaustion using the pictorial children’s effort rating 
table (P-CERT) and the 0-10 category ratio (CR-10) scale, respectively, the methodology for 
which is described elsewhere (30).  
 
HHb modelling procedures  
Paragraph 13: Muscle [HHb] data were interpolated to 1-s intervals and averaged data (15-
s) for the entire test were subsequently normalized to the total amplitude of the response 
(%∆[HHb]), such that 0% represented steady-state values observed during the period of 
baseline (20 W) cycling and 100% represented the highest average (i.e., ∆[HHb]peak) (4,11). 
The response was then expressed as a function of absolute and relative PPO and V̇O2max. 
Preliminary statistical analyses (GraphPad Prism, GraphPad Software, San Diego, CA) 
revealed that the sigmoid provided a superior fit to the HHb response when compared with 
bilinear or hyperbolic curve fitting procedures (data not reported). The ∆[HHb] response to 
incremental ramp cycling exercise was therefore described using a sigmoidal model 
(Equation 2) in line with previous studies (4,9,21) as follows: 
 
y = f0 + A / (1 + e 
–(c+dx)
)         Equation 2.  
 
where f0 represents baseline [HHb], A the amplitude of the response, d the slope of the 
sigmoid, c the constant that is dependent on d and c/d the value corresponding to 50% of the 
total amplitude, respectively. 
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Paragraph 14: Statistical Analyses. Log-linear allometric models were used to adjust 
V̇O2max for body size. The log-linear allometric model yielded a scaling exponent close to 
unity for FFM (b = 1.03), meaning the ratio standard method for normalising V̇O2max was 
deemed appropriate.  
Paragraph 15: Data are expressed as means and standard deviations unless otherwise 
stated. Independent samples t-tests (SPSS v19.0, Chicago, USA) derived p-values for 
subsequent inferential analyses. Inferential statistics, using 90% confidence intervals (CI) and 
the effect size (ES), were used to derive magnitude-based inferences regarding the true value 
of the observed effect statistic (15). Facilitated by a published Microsoft Excel
®
 spreadsheet 
(14), any influence of CF on parameters of the [HHb] response and maximal and submaximal 
CPET parameters was calculated, using a 90% CI and the ES. Using a smallest worthwhile 
ES change of 0.2 (5) and the 90% CI, the likelihood that the observed effect was beneficial 
(e.g. higher V̇O2max, faster MRT), trivial or harmful (e.g. lower V̇O2max, slower MRT) was 
reported. The qualitative terms used to inform these decisions were: < 0.5%, ‘most unlikely’; 
0.5-5%, ‘very unlikely’; 5-25%, ‘unlikely’; 25-75%, ‘possibly’; 75-95%, ‘likely’; 95-99.5%, 
‘very likely’; > 99.5%, ‘most likely’. An effect was deemed trivial when the majority (> 
50%) of the 90% CI resided between beneficial and harmful. Conversely, an effect was 
deemed unclear when the likelihood of a beneficial and harmful effect was > 5%.  
Paragraph 16: Hopkins’ published spreadsheet (14) was also used to determine the 
90% CI for Pearson’s correlation coefficients to explore the relationship between key 
parameters of aerobic function (i.e., V̇O2max, V̇O2 gain, MRT and the GET) and 
mechanistically linked parameters of muscle O2 extraction (e.g., d and c/d of the [HHb] 
response) and O2 delivery (e.g., end-exercise SpO2% and O2 pulse) in CF. Cohen’s thresholds 
(4) for small (0.1), moderate (0.3), large (0.5) and very large (0.7) relationships describe the 
magnitude of correlations.  
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RESULTS 
Paragraph 17: Table 1 presents participants’ baseline physical characteristics, with Table 2 
detailing the clinical profile of the patients with CF. Body mass index (BMI) was likely 
higher, whereas FEV1 (% predicted) was likely lower in CF than CON. Pubertal maturity of 
both groups were as follows: pre-pubertal (n in CF = 3; n in CON = 1), circum-pubertal (n in 
CF = 7; n in CON = 8) and post-pubertal (n in CF = 0; n in CON = 1).  
Paragraph 18: Maximal and submaximal CPET parameters are presented in Table 3. 
All participants completed CPET without any adverse events. Ramp PPO was possibly lower 
in CF and likely lower when expressed relative to body mass. As expected, CF presented 
with very likely reduced V̇O2max, when normalized for both body mass and FFM. 
Furthermore, the V̇O2 gain was very likely lower and the V̇O2 MRT was likely slowed in CF. 
The RPD upon exhaustion was most likely higher in CF, respectively.  
Paragraph 19: Parameter estimates for normalized muscle [HHb] as a function of 
absolute and percentage PPO (%PPO) and V̇O2max (%V̇O2max) are compared in Table 4, and 
the Δ[HHb]-WR profile for two representative CF and CON matched pairs are shown in 
Figure 1. Any effect of the reduced aerobic fitness in patients with CF upon the slope (d) of 
the Δ[HHb]-WR response was mechanistically unclear when expressed either as a function of 
absolute and percentage PPO or absolute and percentage V̇O2max. Furthermore, the effect of 
CF upon the absolute and relative WR and V̇O2 corresponding to 50% [HHb] amplitude (c/d) 
was mechanistically unclear.  
Paragraph 20: Correlational analyses within the CF group revealed small 
relationships between patients’ V̇O2max and their [HHb] c/d, expressed as a function of %PPO 
(r =0.14, ±0.58) and %V̇O2max (r = -0.21, ±0.57), respectively. With the exception of the very 
large relationship between V̇O2 gain and [HHb] c/d %PPO (r = 0.70, ±0.36), relationships 
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between V̇O2 gain and [HHb] c/d %V̇O2max and the GET and MRT with [HHb] c/d %PPO and 
%V̇O2max were all small. A moderate relationship was observed between V̇O2max and end-
exercise SpO2% (r = 0.33, ±0.51) in CF (Figure 2), however this was small (r = 0.20, ±0.54) 
in the healthy control group. The relationship between V̇O2max and O2 pulse was large in CF (r 
= 0.58, ±0.41; Figure 2) and CON (r = 0.98, ±0.00). Similarly, the relationships between V̇O2 
gain and end-exercise SpO2% and O2 pulse were moderate (r = 0.40, ±0.49) and large (r = 
0.65, ±0.37), respectively in CF, however these were small in CON (r = -0.15, ±0.54 and r = 
0.1, ±0.58, respectively). Very large relationships were also evident between the GET and 
end-exercise SpO2% (r = -0.88, ±0.16) and O2 pulse (r = 0.98, ±0.03) in CF. The relationship 
between the GET and O2 pulse was very large in CON (r = 0.92, ±0.12); however that with 
SpO2% was small (r = 0.1, ±0.55). A moderate relationship (r = 0.39, ±0.49) was also evident 
between the V̇O2 gain and MRT in CF, however this was small in CON (r = 0.01, ±0.55).  
 
DISCUSSION  
 
Paragraph 22: This is the first study to examine the influence of mild-to-moderate CF on the 
aerobic function and dynamic adjustments in localized muscle (vastus lateralis) fractional 
oxygen extraction (∆[HHb]) in pediatric patients during ramp incremental cycling exercise.  
As expected, CF patients were characterized by impaired aerobic function, as displayed by a 
very likely reduced body mass or FFM normalized V̇O2max, a very likely lower V̇O2 gain, and 
likely slower V̇O2 MRT. Contrary to the experimental hypothesis, however, this reduced 
aerobic fitness status did not have a clear effect upon the dynamics of the ∆[HHb] during 
ramp incremental exercise. Specifically, no clear shift in c/d of the [HHb] response was 
evident when expressed relative to percentage PPO or V̇O2max and relationships with the key 
parameters of aerobic fitness were small. Indicators of central O2 delivery were, however, 
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altered by CF. Specifically, end-exercise SpO2% was most likely lower and correlated with 
V̇O2max in the CF group only. Thus, these data show that the observed changes in the aerobic 
function of pediatric patients with CF during incremental ramp cycling are likely related to 
alterations in muscle O2 delivery, with no compensatory adjustment to the dynamics of 
muscle O2 extraction within the microcirculation.   
Paragraph 23: This study is unique for a number of reasons. It is the first to use a 
validated protocol (30) to document ‘true’ V̇O2max in young patients with CF. Consistent with 
earlier reports (18), V̇O2max in patients with CF was very likely lower than that of CON in this 
study when normalized for both body mass and FFM. But importantly, the present results are 
robust because this is the first to include a supramaximal V̇O2max verification phase (30) 
within the CPET protocol, thereby removing the issue of previous studies, where aerobic 
fitness status may have been underrepresented because of invalid verification criteria (30).  
Paragraph 24: Secondly, this study presents, for the first time, the four key 
parameters of aerobic function (37), allowing a comprehensive assessment of aerobic fitness 
in this patient group. Of the additional key parameters, patients with CF presented with a very 
likely reduced V̇O2 gain and a likely slowed V̇O2 MRT, with no clear effect on the GET. 
While slower pulmonary V̇O2 kinetics have been documented in patients with CF during 
constant-load, moderate intensity cycling (13), the present study extends these findings to the 
V̇O2 response at the onset of ramp incremental cycling. Although no clear influence upon the 
GET was evident, the functional gain during the moderate-intensity region of ramp exercise 
was very likely lower in CF, reflecting either an apparently greater skeletal muscle efficiency 
or impaired muscle O2 consumption. Shallower ∆V̇O2/∆WR slopes during exercise have 
previously been reported in patients with CF (22), congenital heart disease (12) and juvenile 
dermatomyositis (12). However, steeper ∆V̇O2/∆WR responses have also been observed in 
young patients with CF (12). It would be misleading to interpret the reduced ∆V̇O2/∆WR in 
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the present findings as enhanced aerobic efficiency, particularly given the impairment in 
other parameters of aerobic function (i.e., V̇O2max and MRT). Given the moderate relationship 
between the V̇O2 gain and MRT in CF, the lower ∆V̇O2/∆WR slope may be related to the 
slower pulmonary V̇O2 kinetics, such that the rise in V̇O2 was not sufficiently rapid to respond 
to the work rate increments during the CPET. 
Paragraph 25: To our knowledge, this study is the first to report the ∆[HHb] 
dynamics during ramp exercise in pediatric patients with CF. While pulmonary V̇O2 increased 
linearly with increasing work rate following an initial time lag, muscle ∆[HHb] (reflecting the 
ratio of muscle blood flow to muscle O2 utilisation (Table 4; Figure 1)) increased in a 
nonlinear manner. This response was well characterized using a sigmoid function relative to 
WR and V̇O2 in both groups in the current study, which is consistent with previous reports in 
children and young and old adults during ramp cycling exercise (4,11,21).  
 Paragraph 26: Contrary to the study hypothesis, the ∆[HHb] dynamics during ramp 
exercise were similar between CF and CON in the present study. That is, no clear effect of 
CF upon either the absolute and relative WR and V̇O2 corresponding to 50% ∆[HHb] 
amplitude was observed. This is despite previous reports that aerobic fitness status has an 
effect upon the dynamic balance between O2 supply and demand and, consequently, the 
sigmoidal pattern of [HHb] (4,21). Boone et al. (4) previously demonstrated that a higher 
aerobic fitness is associated with a rightward shift of the [HHb] sigmoidal response (relative 
to %PPO) in healthy adults and that the response correlated with parameters of aerobic fitness 
(i.e., V̇O2max and the GET). The purported mechanism for this rightward shift in the [HHb] 
response was attributed to a higher oxidative capacity and/or altered muscle fiber distribution. 
The rate of fractional oxygen extraction has been shown to be influenced by training status 
and enhanced O2 delivery in trained versus untrained healthy girls (21). Because V̇O2max was 
meaningfully reduced in patients with CF in the present study, a more rapid increase in 
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∆[HHb] during ramp exercise would be expected. However, a previous study (11) comparing 
older (approximately 70 yr) and younger (approximately 25 yr) healthy adults, which 
observed alterations when expressed relative to absolute power output, did not observe any 
age-related differences in ∆[HHb] response dynamics when expressed as a function of 
%PPO, despite a reduced V̇O2max in the older participants (30 vs. 49 mL·kg
-1
·min
-1
).  
Paragraph 27: Some caution may, however, be applied when considering the present 
findings to suggest that there are no differences between the ∆[HHb] response of healthy and 
CF children and adolescents. Inter-patient differences (Figure 1) in the Δ[HHb] response 
suggest that the interpretation that the rate of muscle O2 extraction is unaltered by CF may be 
too simplistic. When the distribution of the 90% CI for the effect of CF on the ∆HHb c/d was 
expressed relative to percentage V̇O2max, the majority of the 90% CI distribution favoured a 
reduced rate of extraction (leftward shift: 9%; trivial: 22%; rightward shift: 69%). The 
unclear statistical outcome is, therefore, likely to reflect the large inter-patient variability 
present for this outcome (see Figure 1). Indeed, inter-patients differences are not improbable 
given the complex nature and varied clinical presentation of CF disease, meaning further 
comment on the responses shown in Figure 1 may be of clinical interest. Patient A, who has a 
left shift on the ∆[HHb] response, is a physically mature boy with few complications and 
excellent lung function. In contract, patient B (also male), whose ∆[HHb] response is shifted 
to the right has poorer lung function, a worse chest x-ray score, nutritional concerns, and 
complications including CF-related liver disease and impaired glucose tolerance. This is 
reflected in patient B having received 28 d of intravenous antibiotics, which signifies 
treatment intensification, within the preceding year. However, despite patient B’s poorer 
clinical profile, his V̇O2max is markedly higher than that of patient A (49.4 vs. 32.6 mL·kg
-
1
·min
-1
), which may have played a role in causing the rightward shift in the ∆[HHb] response 
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dynamics. However, it should be noted that we only found a small relationship between 
V̇O2max and [HHb] c/d in the present study.    
 Paragraph 28: Interestingly, the present findings of unaltered [HHb] response 
dynamics for the CF group in the present study are in line with a previous report by 
Rosenthal et al. (29), who observed similar O2 extraction dynamics during exercise in young 
patients with CFR and their healthy counterparts, despite presenting with impaired aerobic 
function. When considered in reference to the Fick equation, these data therefore suggest that 
the impaired aerobic function characterising young patients with CF is caused by a reduction 
in O2 delivery. Altered cardiac function (3,16,27) and an inability to augment SV during 
exercise (29), which are likely to reduce central O2 delivery, have previously been 
documented in patients with CF, and the most likely lower SpO2% in the present study 
provides further support. Although it has been propositioned that patients with CF can 
achieve apparently “normal” cardiac output in the presence of reduced SV during exercise, 
through elevated HR (16,20), this compensation only seems viable at submaximal exercise 
intensities, as both CF and CON had similar HR responses at maximal exercise in the present 
study. In accordance with this findings, a reduced (approximately 24%) estimated SV 
(derived using respiratory mass spectroscopy) at maximal exercise in young patients with CF 
coupled with a similar HR response to healthy controls has previously been documented (29).  
 Paragraph 29: Although it has been hypothesized that patients limited by O2 delivery 
during exercise would present with a compensatory increase in O2 extraction at the local level 
(9), both this study and the previous study by Rosenthal et al. (9), using respiratory mass 
spectroscopy, observed no augmentation of O2 extraction in the face of inadequate O2 
delivery during exercise (29). Although the previous authors could not determine the cause of 
this because no direct peripheral measurements were made, it was suggested that muscle 
metabolic issues resulting from chronic bronchial sepsis may contribute. Importantly, the 
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present study utilising NIRS corroborates the observations of Rosenthal et al. (29) using a 
more direct measurement technique.  
Paragraph 31: The relationships between parameters of aerobic function and 
mechanistic parameters indicative of O2 delivery and extraction further emphasize the 
importance of O2 delivery in explaining the impaired aerobic function in young patients with 
CF. Although the relationships between key parameters of aerobic function and the rate of 
peripheral fractional O2 extraction were small, stronger relationships with parameters of O2 
delivery were evident. Furthermore, while SpO2% did not correlate with FFM normalized 
V̇O2max in healthy controls, a moderate correlation with end-exercise SpO2% was observed in 
patients with CF, along with a large relationship between V̇O2max and the O2 pulse. The 
relationships between V̇O2 gain and end-exercise SpO2% and O2 pulse were also moderate and 
large, respectively. Similarly, very large relationships were evident between the GET and 
end-exercise SpO2% and O2 pulse.  
  Paragraph 32: There are several limitations of NIRS, which must be acknowledged. 
First, measurements are restricted to a specific area of interrogation over a, in this case, single 
heterogenous and superficial muscle, which may not represent whole body skeletal muscle 
blood flow responses. However, the muscle deoxygenation response measured in the 
superficial and deeper muscle fibres using NIRS has been shown to reflect muscle 
oxygenation as measured using phosphorous quenching derived microvascular O2 partial 
pressure within the same region of muscle (18). Although inter-site variation in the [HHb] 
response cannot be directly rectified, the device was secured to the same anatomical region 
for all participants to eradicate inter-individual regional differences within the m. vastus 
lateralis. Although the influence of adipose tissue at the area of interrogation was not directly 
determined, in line with recommendations, responses were standardized to the total [HHb] 
amplitude to provide a physiologic normalization (4). Finally, the generalizability of these 
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findings should be viewed in light of the small sample of Northern European patients with CF 
recruited for this study.  
 Paragraph 33: To conclude, this was the first study to examine the influence of mild-
to-moderate CF on key parameters of aerobic function in pediatric patients. As expected, 
pediatric patients presented with impaired aerobic fitness compared with that of their healthy 
counterparts. Specifically,V̇O2max and the V̇O2 gain were very likely reduced and the MRT 
likely slowed. However, in contrast to the study hypothesis, NIRS derived [HHb] dynamics 
during ramp cycling exercise were similar between CF and CON. The present findings 
support the notion of centrally mediated oxygen delivery principally limiting the aerobic 
function of young patients with CF during ramp incremental cycling exercise. 
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FIGURE LEGENDS 
 
 
Figure 1. Sigmoid models of normalized muscle deoxygenation (% ∆[HHb]) during ramp 
incremental exercise as a function of percentage peak oxygen uptake for two representative 
young patients with CF (●, black circles) of the leftward and rightward response patterns and 
their healthy age- and gender-matched control participants (dashed line; ○, white circles).  
 
 
Figure 2. The relationship between V̇O2max and changes in end-exercise SpO2% and the 
maximal oxygen pulse in young patients with CF.  
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Figure 2 
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TABLES 
 
Table 1. Baseline anthropometric and pulmonary function data for young CF patients (n = 
10, 1 female) and healthy age- and gender-matched controls. 
Variable CF 
(Mean ± SD) 
CON  
(Mean ± SD) 
Change,  
90% CL 
Inference 
(in CF) 
ES 
      
Age (y) 
 
12.7 ± 2.8 12.5 ± 2.8 0.2, ±2.2 Unclear 0.07 
Stature (m) 
 
1.53 ± 0.15 1.58 ± 0.19 -0.05, ±0.14 Unclear -0.25 
Body mass (kg) 
 
53.2 ± 20.0 50.5 ± 17.4 2.7, ± 14.6 Unclear 0.14 
BMI (kg·m
2
) 
 
22.0 ± 4.6 19.5 ± 2.7 2.4, ±3.0 Likely higher  0.60 
BSA (m
2
) 
 
1.51 ± 0.35 1.48 ± 0.35 0.03, ±0.27 Unclear  0.08 
FFM (kg) 
 
42.0 ± 14.6 41.3 ± 14.0 0.6, ±11.1 Unclear 0.04 
FVC (L) 
 
3.36 ± 1.30  
 
3.69 ± 1.33 -0.33, ±1.03 Unclear -0.24 
FVC ( % predicted  
(range)) 
102 ± 14 
(79-123) 
106 ± 10 
(92-125) 
-4, ±10 Unclear -0.28 
 
FEV1 (L) 
 
 
2.69 ± 1.12 
 
3.18 ± 1.18 
 
-0.49, ±0.89 
 
Unclear 
 
-0.41 
FEV1 (% predicted 
(range)) 
97 ± 22 
(66-127) 
107 ± 10 
(96-129) 
-10, ±14 Likely lower -0.55 
 
Values are means ± SD. ES; Effect size; CI, confidence intervals; BMI, body mass index; FFM, fat-free mass 
(calculated using the equation of Slaughter et al. (32); FVC, forced vital capacity; FEV1, forced expiratory 
volume in 1 second. N.B. Parameters of pulmonary function are expressed as a percentage predicted normal 
using appropriate reference data (33).  
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Table 2. Baseline clinical characteristics for the young CF patients (n = 10, 1 female).  
 
Variable Value (mean ± SD) Range 
CFTR genotype: 
Homozygote ∆F508 (Class I mutation) 
∆F508/ 2184delA (Class II Mutation) 
∆F508/ G55ID (Class III mutation) 
- 
8 
1 
1 
- 
- 
- 
- 
Chronic P. Aeruginosa infection
 a “chronic,” n = 2; 
“intermittent,” n = 3 
“free,” n = 3 
“never,” n = 2 
Shwachman score 81 ± 7 67-91 
Northern score
 b 
4 ± 1 2-6 
Pancreatic insufficient n = 10  
CF-related diabetes n = 3 - 
CF-related liver disease 
IVABs (days in last year) 
n = 3 
10 ± 15 
- 
0-42 
 
Values are means ± SD, unless otherwise stated. 
CFTR, cystic fibrosis transmembrane conductance regulator; P. Aeruginosa; Pseudomonas Aeruginosa; 
Shwachman score - scoring 4 separate aspects of the disease profile; general activity; physical examination; 
nutritional status; and chest radiographic findings, using the most recent clinical review information. A total of 
100 points represents a perfect score of health; IVABs, intravenous antibiotics; 
a
According to Leeds Criteria, 
“chronic”, >50% of the preceding 12 months were P. aeruginosa culture positive; “intermittent”, ≤50% of the 
preceding 12 months were P. aeruginosa culture positive; “never”, no growth of P. aeruginosa for the previous 
12 months, having previously been P. aeruginosa culture positive; “free”, P. aeruginosa has never been 
cultured.   
b
 Provides evidence of radiographic chest findings. Maximum score is 20, with 20 being the most severe.  
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Table 3. Maximal and submaximal physiologic responses of young patients with CF and 
healthy age- and gender-matched controls to ramp incremental cycle exercise.  
 
Variable CF 
(Mean ± SD) 
CON 
(Mean ± SD) 
Change, 90% 
CI 
Inference 
(in CF) 
ES 
Maximal exercise parameters - - - - - 
Absolute V̇O2max (L∙min
-1
) 1.93 ± 0.84 2.21 ± 0.79 -0.29, ±0.63 Unclear -0.34 
Relative V̇O2max (mL∙kg
-1∙min-1) 
V̇O2max/FFM (mL∙kg
-1∙min-1) 
36.3 ±  7.6 
45.5 ± 9.1 
43.9 ± 5.2 
53.5 ± 6.4 
-7.6, ±5.1 
-7.9, ± 6.1 
Very likely lower  
Very likely lower 
-1.11 
-0.96 
V̇Emax (L∙min
-1
) 84.27  ± 33.07 99.31 ± 39.95 -15.04, ±28.53 Unclear  -0.39 
Breathing reserve (%) 20.4 ± 19.9 12.4 ± 16.2 8.0, ±14.1 Unclear 0.42 
HRmax (beats∙min
-1
) 192 ± 11 190 ± 13 2, ±10 Unclear 0.18 
V̇O2/HRmax (mL·beat
-1
) 9.78 ± 4.71 11.01 ± 3.39 -1.23, ±3.41 Unclear -0.28 
SpO2 (%) 95 ± 2 97 ± 1 -3, ±1 Most likely lower  -1.63 
Ramp PPO (W) 176 ± 94 205 ± 82 -30, ±69 Possibly lower -0.32 
Relative ramp PPO (W·kg
-1
) 3 ± 1 4 ± 1 -0.7, ±0.5 Likely lower -0.84 
RPE 9 ± 2 10 ± 1 -1, ±1 Unclear -0.35 
RPD 9 ± 2 6 ± 2 3, ±2 Most likely higher 1.46 
Submaximal exercise  - - - - - 
V̇O2 at the GET (L∙min
-1
) 1.13 ± 0.41 1.20 ±  0.30  -0.07, ±0.28 Unclear -0.20 
GET% (% of V̇O2max) 61.3 ± 10.2 56.7 ± 8.4 4.6, ±7.3 Unclear 0.47 
MRT (s) 49 ± 21 38 ± 11 11, ±13 Likely slower 0.63 
ΔV̇O2/ΔWR (mL∙min
-1∙W-1) 7.62 ± 1.67 9.05 ± 1.17 -1.44, ±1.12 Very likely lower  -0.95 
 
Values are means ± SD. 
RPE, RPD and SpO2% were measured at the end of exercise.  
ΔV̇O2/ΔWR, oxygen cost of exercise (efficiency); GET, non-invasive estimate of the lactate threshold which 
was verified by the ventilatory threshold; GET%, GET expressed as a percentage of V̇O2max; MVV, maximal 
voluntary ventilation; V̇O2max, maximal oxygen uptake; MVV, maximal voluntary ventilation; V̇O2/HRmax, 
maximal oxygen pulse; V̇Emax, maximal minute ventilation; V̇O2/HRmax, maximal oxygen pulse; V̇E/V̇CO2-slope, 
ventilatory drive. 
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Table 4. Parameter estimates for normalized muscle deoxygenation (∆[HHb]) as a function 
of absolute and percentage PPO during ramp incremental cycling and the absolute and 
normalized ratio of HHb-to-pulmonary oxygen uptake above and below the GET and at 
exhaustion. 
 
Variable Parameter 
expressed 
function 
of 
CF (n = 9) 
(Mean ± SD) 
CON (n = 9) 
(Mean ± SD) 
Change, 
90% CI 
Inference 
(in CF) 
ES 
A (%) PPO 100.1 ± 18.0 96.1 ± 8.1 4.0, ±11.8 Unclear 0.27 
d (%·W
-1
) PPO 0.1 ± 0.1 0.1 ± 0.0 0.0, ±0.1 Unclear 0.40 
c/d (W) PPO 98 ± 52 112 ± 54 -14, ±44 Unclear  -0.25 
A (%) %PPO 100.0 ± 17.8 96.1 ± 8.1 3.9, ±11.7 Unclear 0.26 
d (%·%peak
-1
) %PPO 0.1 ± 0.1 0.1 ± 0.0 0.0, ±0.0 Unclear 0.16 
c/d (%peak) %PPO 47.1 ± 17.8 47.7 ±  9.1 -0.7, ±12.0 Unclear -0.04 
A (%) V̇O2max 88.2 ± 10.2 93.6 ± 6.8 -5.4, ±7.2 Likely lower -0.59 
d (%·L
-1
) V̇O2max 13.3 ± 16.4 6.9 ± 4.3 6.3, ±10.4 Unclear 0.48 
c/d  (L) V̇O2max 1.27 ± 0.51 1.36 ± 0.52 -0.10, ±0.43 Unclear -0.18 
A (%) %V̇O2max 91.6 ± 9.0 93.5 ± 6.8 -1.9, ±6.6 Unclear -0.23 
d (%·%max
-1
) %V̇O2max 0.2 ± 0.1 0.1 ± 0.0 0.0, ±0.1 Unclear 0.38 
c/d (%max) %V̇O2max 66.9 ± 8.5 63.6 ± 5.7 3.3, ±6.0 Unclear 0.43 
 
 
Values are means ± SD unless otherwise stated. 
Because of technical issues, [HHb] data are presented for nine matched pairs.  
A, amplitude of the change in the deoxygenated hemoglobin (Δ[HHb]) response; c, constant that is dependent 
upon d and where c/d x-value corresponding to 50% A, respectively; d, slope of sigmoid.  
